



DJ-A-03

1648/10  
PATENT  
454313-2250.1 #10

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : AUDONNET et al.  
Serial No. : 10/085,519  
For : POLYNUCLEOTIDE VACCINE FORMULA IN  
PARTICULAR AGAINST BOVINE  
RESPIRATORY PATHOLOGY  
Filed : February 28, 2002  
Examiner : Z. Lucas  
Art Unit : 1648

ext. 2(mao.)  
Amdt C  
3/28/03  
**RECEIVED**

MAR 27 2003

TECH CENTER 1600/2900

745 Fifth Avenue  
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV 195878350 US

Date of Deposit: March 17, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

Charles Jackson

(Typed or printed name of person mailing paper or fee)

Charles Jackson

(Signature of person mailing paper or fee)

**AMENDMENT AND RESPONSE TO OFFICE ACTION  
WITH REQUEST FOR EXTENSION OF TIME**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed on December 16, 2002, setting a one month term for reply.

**PETITION FOR EXTENSION OF TIME**

Pursuant to 37 C.F.R. §1.136(a) and §1.17(a), a two-month extension of the period for reply, i.e., to up to and including March 17, 2003 (as March 16 was a Sunday) is requested. The Commissioner is hereby authorized to charge the \$410.00 fee and any additionally required fee for this extension of time or any other fee occasioned by this paper, or credit any overpayment in such fees, to Deposit Account No. 50-0320.

03/21/2003 RMEBRAHT 00000096 500320 10085519

01 FC:1252 410.00 CH

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents. Attached is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

In the Claims

12. (Amended) An immunogenic composition for inducing an immunological response against bovine parainfluenza virus type 3 comprising at least one plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding type 3 bovine parainfluenza virus HN protein, or F protein, or HN and F proteins.

13. (Amended) The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell a nucleic acid molecule having a sequence encoding bovine parainfluenza virus type 3 HN protein.

14. (Amended) The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine parainfluenza virus type 3 F protein.

c' 15. (Amended) The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine parainfluenza virus type 3 HN and F proteins.

16. (Amended) A method for inducing an immunological response in a bovine comprising: administering to said bovine a vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, and a recombinant vaccine; and thereafter, administering to said bovine an immunogenic or vaccine composition as claimed in any one of claims 12-15.

17. (Amended) A method for inducing an immunological response in a bovine comprising administering to said bovine an immunogenic or vaccine composition as claimed in any one of claims 12-15.

18. (Amended) A kit comprising (i) an immunogenic composition according to any one of claims 12-15, and (ii) a bovine vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, and recombinant vaccine.